Fibrinolytic Therapy in Purulent Pericarditis.

Area of Science:

• Cardiology
• Infectious Diseases

Background:

• Purulent pericarditis (PP) is a rare condition with nearly 100% mortality if untreated.
• PP frequently leads to constrictive pericarditis (CP), a significant clinical challenge.
• Fibrin deposits in PP impede antibiotic penetration, reducing treatment efficacy.

Purpose of the Study:

• To evaluate the role of intrapericardial fibrinolytic therapy in managing purulent pericarditis.
• To explore strategies for improving antibiotic delivery within the pericardial sac.
• To review current literature and share clinical experiences on this rare condition.

Main Methods:

• Literature review on purulent pericarditis and fibrinolytic therapy.
• Analysis of clinical experiences with intrapericardial drug administration.
• Discussion of antibiotic penetration challenges in PP.

Main Results:

• Fibrinolytic drugs can dissolve fibrin, potentially enhancing antibiotic effectiveness.
• Intrapericardial fibrinolysis may reduce the risk of developing constrictive pericarditis.
• Optimal drug choice, dosage, and administration for fibrinolysis in PP remain under investigation.

Conclusions:

• Urgent pericardial drainage and broad-spectrum antibiotics are crucial for PP management.
• Intrapericardial fibrinolytic therapy is a promising adjunctive treatment for PP.
• Further research is needed to standardize fibrinolytic therapy protocols for PP.